Expand / Collapse search
☰

Novavax begins Phase 3 testing of COVID-19 vaccine candidate

By Associated Press
Updated  December 28, 2020 3:14pm EST
Health
FOX 13 Tampa Bay

Doctor explains how COVID-19 vaccines differ from traditional vaccines

Dr. Chin-Hong explains how COVID-19 vaccines differ from traditional vaccines.

WASHINGTON (AP) - A huge study of another COVID-19 vaccine candidate is getting underway Monday as states in the U.S. continue to roll out scarce supplies of the nation’s first shot options.

The U.S. has authorized emergency use of two vaccines, one made by Pfizer and BioNTech and the other by Moderna, but doses will be rationed for months.

The candidate made by Novavax Inc. is the fifth to reach final-stage testing in the U.S. Some 30,000 volunteers are needed to prove if this vaccine — a different kind than its Pfizer and Moderna competitors — really works and is safe.

RELATED: Volunteers still needed to test variety of coronavirus vaccines

The study, which is funded by the U.S. government, is open to all adults but will focus on high-risk older adults and volunteers from Black and Hispanic communities who have been hard-hit by the virus. Two-thirds of volunteers will receive the vaccine and the rest will get dummy shots.

Medical syringe is seen with Novavax company logo displayed on a screen in the background in this illustration photo taken in Poland on November 16, 2020. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

The Novavax candidate uses lab-grown harmless copies of the spike protein that coats the coronavirus to train the body to recognize if the real virus comes along. The Pfizer and Moderna vaccines instead use a newer technology, injecting the genetic code for that protein.